Application of miR-3065-5p in the preparation of drugs to improve the sensitivity of pancreatic cancer to gemcitabine
By regulating human HMOX-1 gene expression with hsa-miR-3065-5p and utilizing a lipid nanoparticle delivery system, the problem of gemcitabine resistance in pancreatic cancer cells was solved, significantly improving the sensitivity of pancreatic cancer to gemcitabine and inhibiting tumor growth.
Patent Information
- Application Number
- CN202611479490.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-09-22
- Publication Date
- 2026-11-17
AI Technical Summary
The resistance of pancreatic cancer cells to gemcitabine severely limits its clinical efficacy, and existing technologies are insufficient to effectively improve the sensitivity of pancreatic cancer to gemcitabine.
By using hsa-miR-3065-5p to regulate the expression of the human HMOX-1 gene, combined with a lipid nanoparticle delivery system, the sensitivity of pancreatic cancer cells to gemcitabine was improved.
It significantly enhanced the sensitivity of pancreatic cancer cells to gemcitabine, reduced the IC50 value, inhibited tumor growth, and showed a significant sensitizing effect in in vitro and in vivo experiments.
Smart Images

Figure CN123101554A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to the application of hsa-miR-3065-5p in the preparation of drugs that improve the sensitivity of pancreatic cancer to gemcitabine. Background Technology
[0002] Pancreatic cancer is one of the deadliest malignant tumors, and surgical resection combined with chemotherapy remains the primary treatment. Gemcitabine (GEM), as a first-line chemotherapy drug, can induce tumor cell apoptosis by inhibiting DNA synthesis, but the widespread occurrence of drug resistance severely limits its clinical efficacy.
[0003] In recent years, miRNAs, as key regulators of gene expression, have attracted much attention for their role in tumor drug resistance. Dysregulation of some miRNA expression patterns is associated with the establishment and development of many types of cancer. For example, miR-26a has been found to exist as a tumor suppressor gene in ovarian cancer and lung cancer. Conversely, miR-26a expression is increased in glioma and cholangiocarcinoma, indicating its existence as an oncogene (Song Q, Xu K. [MicroRNA-26a and Tumor][J]. Zhongguo Fei Ai Za Zhi =Chinese Journal of Lung Cancer, 2017, 20(11): 769–774.). Summary of the Invention
[0004] In order to improve the sensitivity of pancreatic cancer cells to gemcitabine (GEM or Gem), this invention proposes hsa-miR-3065-5p (miR-3065-5p) which can be used to prepare drugs that improve the sensitivity of pancreatic cancer to gemcitabine.
[0005] This invention first clarifies that miR-3065-5p expression is downregulated in drug-resistant pancreatic cancer cells AsPC-1 and BxPC-3R, suggesting its potential association with gemcitabine resistance. Functional experiments show that restoring miR-3065-5p expression using a miR-3065-5p mimic enhances the sensitivity of drug-resistant cells to gemcitabine, decreases cell proliferation and colony formation, and increases apoptosis. Further mechanistic studies indicate that miR-3065-5p can target and negatively regulate human HMOX-1 (referred to as HMOX-1 in this example), and interference with human HMOX-1 also inhibits the growth of drug-resistant cells and promotes apoptosis, suggesting that miR-3065-5p participates in enhancing the sensitivity of pancreatic cancer to gemcitabine by regulating human HMOX-1.
[0006] This invention further constructed a lipid nanoparticle delivery system encapsulating miR-3065-5p. Results showed that the prepared LNP / miR-3065-5p particles had a diameter of approximately 145 nm, a low PDI (partial ductility index), relatively uniform particle morphology, and good miRNA encapsulation capacity. Stability experiments demonstrated that LNP encapsulation significantly improved the stability of miR-3065-5p in serum and RNase environments, providing a good technical basis for in vitro and in vivo miRNA delivery.
[0007] Cellular experiments demonstrated that LNP / miR-3065-5p effectively increased the level of miR-3065-5p in drug-resistant cells, and, in combination with gemcitabine, significantly inhibited the growth of AsPC-1 and BxPC-3R cells and reduced the gemcitabine IC50 value. 50 In animal experiments, LNP / miR-3065-5p combined with gemcitabine significantly inhibited the growth of BxPC-3R subcutaneous xenografts in nude mice, reduced tumor weight, and downregulated the expression of Ki67 and HMOX-1 in tumor tissue, suggesting that this delivery system also has a certain gemcitabine sensitizing effect in vivo.
[0008] Based on the above, in a first aspect, the present invention provides the use of a human HMOX-1 gene (NCBI Gene ID: 3162) inhibitor in the preparation of a drug that improves the sensitivity of pancreatic cancer to gemcitabine.
[0009] In one embodiment, the human HMOX-1 gene inhibitor is an HMOX-1 siRNA, has-miR-3065-5p, or a has-miR-3065-5p mimic.
[0010] Human HMOX-1 siRNA sequences: Sense: CAACAAGGAGAGCCCAGUCUUTT; Antisense: AAGACUGGGCUCUCCUUGUUGTT;
[0011] Has-miR-3065-5p sequence: UCAACAAAAUCACUGAUGCUGGA;
[0012] Has-miR-3065-5p analog sequence: Sense: UCAACAAAAUCACUGAUGCUGGA; Antisense: CAGCAUCAGUGAUUUUGUUGAUU.
[0013] Secondly, this invention provides the application of a human HMOX-1 gene inhibitor in combination with gemcitabine in the preparation of a drug for treating pancreatic cancer.
[0014] Thirdly, the present invention provides a drug for improving the sensitivity of pancreatic cancer to gemcitabine, wherein the active ingredient in the drug includes a human HMOX-1 gene expression inhibitor, wherein the human HMOX-1 gene inhibitor is an HMOX-1 siRNA, has-miR-3065-5p, or a has-miR-3065-5p mimic.
[0015] In one embodiment, the drug is a lipid nanoparticle (LNP) encapsulating a human HMOX-1 gene inhibitor. The lipid nanoparticle is a human HMOX-1 gene inhibitor encapsulated within liposomes, and the human HMOX-1 gene inhibitor is an HMOX-1 siRNA, has-miR-3065-5p, or a has-miR-3065-5p mimic.
[0016] The preparation method of the lipid nanoparticles includes:
[0017] Step 1: Preparation of LNPs; The liposomes were prepared using DLin-MC3-DMA, DSPC, DMG-PEG2000 and CHOLESTEROL, with a molar ratio of DLin-MC3-DMA, DSPC, DMG-PEG2000 and CHOLESTEROL of 50:10:1.5:38.5.
[0018] Step 2: Mix the liposomes with the HMOX-1 gene inhibitor until homogeneous, and then dialyze to obtain the final product.
[0019] The present invention also provides a drug for treating pancreatic cancer, wherein the active ingredients of the drug include a human HMOX-1 gene expression inhibitor and gemcitabine.
[0020] The beneficial effects of this invention are as follows:
[0021] This invention discovers that miR-3065-5p enhances the sensitivity of pancreatic cancer to gemcitabine by regulating human HMOX-1.
[0022] This invention establishes an LNP / miR-3065-5p nucleic acid delivery system and verifies that it can improve the sensitivity of pancreatic cancer drug-resistant cells to gemcitabine by delivering miR-3065-5p and regulating human HMOX-1 expression. Attached Figure Description
[0023] Figure 1 :BxPC-3, AsPC-1, BxPC-3R IC 50 (A) Parental cell line BxPC-3 GEM IC 50 (B) AsPC-1 cell GEM IC 50(C) Drug-resistant cell line BxPC-3R GEM IC 50 (D) BxPC-3, AsPC-1, and BxPC-3R cell GEMIC 50 Value statistics chart. *** P < 0.001, n = 3, ±s.
[0024] Figure 2 miR-3065-5p expression was downregulated in drug-resistant cell lines AsPC-1 and BxPC-3R. *** P < 0.001.
[0025] Figure 3 GEM IC50 results of AsPC-1 (left) and BxPC-3R (right) cells transfected with miR-3065-5p mimic. 50 Change diagram.
[0026] Figure 4 : Statistical graph of apoptosis and apoptosis rate of AsPC-1 (AB) and BxPC-3R (CD) cells after transfection with miR-3065-5p mimic. *** P < 0.001.
[0027] Figure 5 Image of cell colony formation and colony formation rate of AsPC-1 cells after transfection with miR-3065-5p mimic.
[0028] Figure 6 Prediction and validation of miR-3065-5p target genes. (A) Targetscan database prediction of miR-3065-5p binding to the 3'UTR region of HMOX-1; (B) Dual-luciferase reporter gene assay to detect luciferase activity in AsPC-1 and BxPC-3 cells transfected with HMOX-1 3'UTR plasmid; (C) GEPIA analysis of HMOX-1 expression in pancreatic cancer and normal tissues. * P < 0.05.
[0029] Figure 7miR-3065-5p negatively regulates HMOX-1 expression. (A) RT-qPCR was used to detect the RNA expression level of HMOX-1 in cells transfected with miR-3065-5p mimic; (B) Western blot was used to detect the protein expression level of HMOX-1 in cells transfected with miR-3065-5p mimic; (C) Western blot was used to detect the protein expression level of HMOX-1 in BxPC-3, AsPC-1, and BxPC-3R cells; (D) Western blot was used to detect the protein expression level of HMOX-1 in BxPC-3 cells transfected with miR-3065-5p inhibitor. (***P<0.001).
[0030] Figure 8 Transfection with siHMOX-1 inhibited the growth of drug-resistant cells. The 450nm OD values of AsPC-1 (left) and BxPC-3R (right) cells after siHMOX-1 transfection were measured using CCK8 assay. **P<0.01, ***P<0.001.
[0031] Figure 9 Interference with HMOX-1 increased apoptosis in drug-resistant pancreatic cancer cells. (A) Apoptosis rate of AsPC-1 cells transfected with siHMOX-1 and after drug administration; (B) Apoptosis rate of BxPC-R cells transfected with siHMOX-1 and after drug administration. * P < 0.05, ** P < 0.01, *** P < 0.001.
[0032] Figure 10 Interference with HMOX-1 inhibited the clonogenic ability of pancreatic cancer drug-resistant cells. Effects of siHMOX-1 transfection on clonogenic rate in AsPC-1 cells (AB); Effects of siHMOX-1 transfection on clonogenic rate in BxPC-3R cells (CD). * P < 0.05, ** P < 0.01, *** P < 0.001.
[0033] Figure 11 : miRNA-LNP particle size and electron micrographs. (A) LNP / NC particle size; (B) TEM characterization results of LNP / miR-3065-5p morphology. Image scale bar is 100 μm; (C) Polydispersity index (PDI) and Zeta potential of LNPs.
[0034] Figure 12 Agarose gel electrophoresis was used to detect the encapsulation effect and stability of LNP / miR-3065-5p. (A) Agarose gel electrophoresis characterizes the encapsulation capacity of LNP for miRNA; agarose gel electrophoresis characterizes the stability of LNP / miR-3065-5p in serum (B) and RNase (C).
[0035] Figure 13 The growth of pancreatic cancer cells was significantly inhibited under combined treatment with LNP / miR-3065-5p and GEM. (A, B) RT-qPCR verified the delivery efficiency of LNP / NC and LNP / miR-3065-5p; (CD) CCK-8 assay determined the growth curves of drug-resistant cells after combined administration of LNP / miR-3065-5p and GEM. Values are expressed as mean ± standard deviation. **P < 0.01, ***P < 0.001.
[0036] Figure 14 LNP / miR-3065-5p combined with GEM enhances the sensitivity of pancreatic cancer. (A) IC50 of AsPC-1 cells transfected with LNP / NC and LNP / miR-3065-5p 50 (B) IC50 of BxPC-3R cells transfected with LNP / NC and LNP / miR-3065-5p 50 n=3, the numerical values are based on n=3. ±s indicates the mean. *P<0.05, ***P<0.001.
[0037] Figure 15 LNP / miR-3065-5p enhanced the sensitivity of subcutaneous pancreatic cancer xenografts to GEM. (A) Changes in tumor volume during drug or blank control group treatment; (B) Mouse weight statistics during the experiment; (C) Photographs of tumors removed after euthanizing nude mice in each group; (D) Tumor weight statistics. n=6, ±SEM. *P<0.05, **P<0.01, ***P<0.001.
[0038] Figure 16 Immunohistochemical results of tumor tissue. Immunohistochemical detection of Ki67 (left) and HMOX-1 (right) expression in tumor tissue.
[0039] In the above diagram, BxPC-3 / Gem represents BxPC-3R. mimic NC represents NC mimic, and mimic miR-3065-5p represents miR-3065-5p mimic. Detailed Implementation
[0040] To make the objectives, technical solutions, and advantages of this invention clearer, the technical solutions in the embodiments of this invention will be clearly described below. Obviously, the described embodiments are only some, not all, of the embodiments of this invention. Based on the embodiments of this invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of this invention.
[0041] Human pancreatic cancer cell lines BxPC-3 and AsPC-1 were preserved at the First Affiliated Hospital of Zhengzhou University. Cells were cultured in RPMI-1640 medium supplemented with 10% v / v fetal bovine serum and 1% v / v penicillin-streptomycin, in an incubator at 37°C and 5% CO2. Gemcitabine used in these examples was gemcitabine hydrochloride.
[0042] Example 1
[0043] 1. Construction of drug-resistant pancreatic cancer cells
[0044] The parental cells BxPC-3 were induced to acquire drug resistance by escalating gemcitabine (GEM) concentration, resulting in the drug-resistant cell line BxPC-3R.
[0045] 2. Gemcitabine-sensitive and drug-resistant cell IC 50 Measurement
[0046] Human pancreatic cancer cell lines BxPC-3, AsPC-1, and drug-resistant cell line BxPC-3R were selected as research subjects. Figure 1 As shown, the three cell types exhibited different sensitivities to GEM, all changing in a concentration-dependent manner. Parental cells BxPC-3IC 50 The value is (2.32±0.25)nM. Figure 1 A), AsPC-1 cell line IC 50 The value is (415.6±23.76)nM ( Figure 1 B); Drug-resistant cells BxPC-3R IC 50 The value is (786.1±52.15)nM. Figure 1 C), where BxPC-3 parental cells showed an IC50 response to GEM. 50 Lowest, highest sensitivity ( Figure 1 D). Therefore, AsPC-1 and BxPC-3R cells were selected as subjects for drug resistance research to explore methods to improve the sensitivity of pancreatic cancer to GEM.
[0047] 3. miR-3065-5p expression is downregulated in drug-resistant pancreatic cancer cells.
[0048] MicroRNA sequencing analysis was performed on drug-resistant cells BxPC-3R and parental cells BxPC-3. RT-qPCR validation was performed by extracting RNA from drug-resistant cells BxPC-3R, AsPC-1, and parental cells BxPC-3, revealing that miR-3065-5p was significantly downregulated in the drug-resistant cell line. Figure 2 ).
[0049] Primers used for RT-qPCR:
[0050] miR-3065-5p stem-loop RT primer (for reverse transcription): GTGGTATTCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCCAGC (SEQ ID NO:1).
[0051] miR-3065-5p upstream primer (for qPCR forward amplification): GGCGCGCTCAACAAAATCACTGAT (SEQ ID NO:2).
[0052] Universal downstream primer (for reverse amplification of qPCR): ATCCAGTGCAGGGTCCGAGG (SEQ ID NO:3).
[0053] 4. Transfection with miR-3065-5p mimic increases the sensitivity of pancreatic cancer cells to GEM.
[0054] To verify whether there is a link between miR-3065-5p and GEM resistance, a miR-3065-5p mimic was designed. GEM was administered to drug-resistant AsPC-1 and BxPC-3R cells transfected with NC mimic (control) and miR-3065-5p mimic, and the IC50 of pancreatic cancer drug-resistant cells to GEM was measured. 50 change.
[0055] Among them, the NC mimic sequences are: Sense: UUGUACUACACAAAAGUACUG (SEQ ID NO:4); Antisense: AAUCUCUAUUCCAGCCUCUAAUU (SEQ ID NO:5).
[0056] miR-3065-5p mimic sequence: Sense: UCAACAAAAUCACUGAUGCUGGA (SEQ ID NO: 6); Antisense: CAGCAUCAGUGAUUUUGUUGAUU (SEQ ID NO: 7).
[0057] The results showed that, compared with the control group, AsPC-1 cells transfected with miR-3065-5p mimic and then treated with GEM showed an IC50 increase. 50 The IC50 concentration in BxPC-3R cells decreased from 0.32 μM to 0.12 μM. 50 The concentration decreased from 0.65 μM to 0.35 μM. Figure 3 This significantly enhanced the efficacy of GEM drugs.
[0058] To further explore the association between miR-3065-5p and GEM resistance in pancreatic cancer cells, AsPC-1 and BxPC-3R cells were transfected with miR-3065-5p mimic and then subjected to GEM. Cell apoptosis was detected by flow cytometry. Four cell groups were established: transfected with NC mimic, transfected with miR-3065-5p mimic, transfected with NC mimic followed by GEM, and transfected with miR-3065-5p mimic followed by GEM. FITC-Annexin V / PI double staining was used to detect apoptosis in AsPC-1 and BxPC-3R cells after transfecting with NC mimic, transfected with miR-3065-5p mimic, transfected with NC mimic followed by GEM, and transfected with miR-3065-5p mimic followed by GEM.
[0059] The results are as follows Figure 4 As shown, compared with the group transfected with NC mimic and then treated with GEM, the AsPC-1 and BxPC-3R cells transfected with miR-3065-5p mimic and then treated with GEM showed significantly increased apoptosis. This result suggests that miR-3065-5p is associated with GEM resistance in pancreatic cancer cells, and that transfection with miR-3065-5p mimic increases the sensitivity of drug-resistant pancreatic cancer cells to GEM.
[0060] To further investigate the effects of miR-3065-5p mimic, a colony formation assay was conducted to study the influence of GEM administration following miR-3065-5p mimic transfection on the cloning ability of two drug-resistant pancreatic cancer cell lines, AsPC-1 and BxPC-3R. The results showed that, compared with the control, GEM administration after miR-3065-5p mimic transfection significantly reduced cell colony formation and inhibited cell growth. Figure 5 ).
[0061] 5. Prediction and validation of miR-3065-5p target genes
[0062] To investigate the mechanism by which miR-3065-5p affects gemcitabine resistance in pancreatic cancer cells, four databases, including TargetScan and miRDB, were used to predict the target genes of miR-3065-5p. The intersection of the predicted target genes was analyzed, and HMOX-1 was ultimately selected for target gene testing of miR-3065-5p. TargetScan database prediction results showed that miR-3065-5p can bind to the 3'UTR region of HMOX-1. Figure 6 A).
[0063] We designed and synthesized the HMOX-1 3'UTR WT / Mut plasmid and performed dual-luciferase reporter gene assay to verify whether miR-3065-5p could bind to the 3'UTR end of the HMOX-1 gene. The 3'UTR-NC, HMOX-1 3'UTR WT, and HMOX-1 3'UTR Mut plasmids were constructed and synthesized by Qingke Biotechnology. The results showed ( Figure 6 (B) Compared with the NC mimic group, miR-3065-5p mimic reduced luciferase activity in the HMOX-1 3'UTR WT plasmid transfected group, while no significant change was observed in the 3'UTR Mut group transfected with HMOX-1.
[0064] To further investigate target genes, the expression of HMOX-1 in pancreatic cancer and normal tissues was analyzed using the GEPIA online analysis tool (https: / / gepia.cancer-pku.cn). The results showed that HMOX-1 expression was higher in pancreatic cancer tissues than in normal pancreatic tissues (P < 0.05). Figure 6 C).
[0065] The above results indicate that HMOX-1 may be a target gene of miR-3065-5p.
[0066] To further investigate the effect of miR-3065-5p on HMOX-1 expression, RT-qPCR and Western blot were used to detect changes in HMOX-1 mRNA and protein expression after transfection with NC mimic or miR-3065-5p mimic into drug-resistant cells. The qPCR primer sequences for HMOX-1 were as follows: upstream: AAGACTGCGTTCCTGCTCAAC (SEQ ID NO:8); downstream: AAAGCCCTACAGCAACTGTCG (SEQ ID NO:9).
[0067] The results showed that, compared with the control (transfected with NC mimic), transfection with miR-3065-5p mimic downregulated both HMOX-1 gene and protein expression. Figure 7 A-7B).
[0068] Furthermore, the protein expression levels of HMOX-1 differed among the three cell lines BxPC-3, AsPC-1, and BxPC-3R, which exhibited varying sensitivities to GEM. Figure 7 C), with the increase of cellular drug resistance, HMOX-1 protein expression increased accordingly. In addition, the protein expression level of HMOX-1 was increased in sensitive BxPC-3 cells transfected with miR-3065-5p inhibitor (control group transfected with NC inhibitor). Figure 7 D). Among them, the NC inhibitor sequence is: CAGUACUUUUGUGUAGUACAA (SEQ ID NO:10), and the miR-3065-5 pin inhibitor is: UCCAGCAUCAGUGAUUUUGUUGA (SEQ ID NO:11).
[0069] The above results indicate that HMOX-1 may be a target gene of miR-3065-5p, and miR-3065-5p can negatively regulate HMOX-1 expression.
[0070] 6. Interference with HMOX-1 expression inhibits the growth of pancreatic cancer cells and increases cell sensitivity to gemcitabine.
[0071] To investigate the effects of HMOX-1 on drug-resistant pancreatic cancer cells AsPC-1 and BxPC-3R, siRNA of HMOX-1 (siNC as a negative control) was designed and synthesized. siHMOX-1 was used to interfere with HMOX-1 expression, and its effects on the growth and GEM sensitivity of pancreatic cancer cells AsPC-1 and BxPC-3R were detected by CCK8 assay. Specifically, BxPC-3R and AsPC-1 cells in the experimental group were transfected with siHMOX-1 or transfected with siHMOX-1 followed by GEM; control group cells were transfected with siNC or transfected with siNC followed by GEM. Among them, siNC sequence: Sense: UUCUCCGAACGUGUCACGUTT (SEQ ID NO: 12); Antisense: ACGUGACACGUUCGGAGAATT (SEQ ID NO: 13); siR-HMOX-1 sequence: sense: CAACAAGGAGAGCCCAGUCUUTT (SEQ ID NO: 14); Antisense: AAGACUGGGCUCUCCUUGUUGTT (SEQ ID NO: 15).
[0072] The results showed that, compared with the control group, cell growth was inhibited after transfection with siHMOX-1 followed by GEM administration. Figure 8 ).
[0073] To further explore the correlation between HMOX-1 and apoptosis in drug-resistant pancreatic cancer cells, cell apoptosis was detected by flow cytometry after interfering with HMOX-1 expression. Experimental BxPC-3R and AsPC-1 cells were transfected with siHMOX-1 or transfected with siHMOX-1 followed by GEM. Control cells were transfected with siNC or transfected with siNC followed by GEM. Results showed that compared with the control group, apoptosis was increased in BxPC-3R and AsPC-1 cells transfected with siHMOX-1 followed by GEM. Figure 9 ).
[0074] The effect of HMOX-1 knockdown on the clonogenic ability of drug-resistant cells was investigated. AsPC-1 and BxPC-3R cells were transfected with siHMOX-1 or transfected with siHMOX-1 followed by GEM. The effect of HMOX-1 knockdown on cell clonogenic ability was examined. Control cells were transfected with siNC or transfected with siNC followed by GEM. The results are as follows: Figure 10 As shown: Compared with the control group, the cell colony formation rate was significantly reduced after HMOX-1 knockdown and treatment with GEM drug.
[0075] Example 2
[0076] 1. Preparation of lipid nanoparticles (LNP / miR-3065-5p) loaded with miR-3065-5p
[0077] (1) Preparation of 16 mM lipid (taking 5 mL volume as an example)
[0078] Cationic liposomes DLin-MC3-DMA (Avitol (Shanghai) Pharmaceutical Technology Co., Ltd.), DSPC (Avitol (Shanghai) Pharmaceutical Technology Co., Ltd.), DMG-PEG2000 (Avitol (Shanghai) Pharmaceutical Technology Co., Ltd.), and CHOLESTEROL (Xiamen Sinobond Biotechnology Co., Ltd.) were dissolved in chromatographic grade anhydrous ethanol to prepare stock solutions of 128, 16, 8, and 32 mM, respectively. These were then added sequentially to centrifuge tubes at a molar percentage of 50:10:1.5:38.5. For example, with a 5 mL volume, the volumes of stock solutions added to each lipid were 312.5, 500.0, 150.0, and 962.5 μL, respectively. Then, 3075.0 μL of anhydrous ethanol was added, and the mixture was gently inverted and shaken until homogeneous. The aliquots were stored at -20 ℃.
[0079] (2) Preparation of LNP / miR-3065-5p
[0080] ① Aqueous phase preparation: Dissolve and prepare an appropriate concentration of miR-3065-5p simulant in enzyme-free water, then add an appropriate volume of 0.1M sodium citrate buffer (pH 4.0, adjust the volume according to the lipid concentration), mix well, and use as an aqueous phase solution for later use.
[0081] ② Organic phase preparation: Adjust the volume according to the lipid concentration to make the nitrogen-phosphorus ratio (N / P ratio) of lipid to miRNA reach 8:1.
[0082] ③ Mixing and self-assembly: Add a stir bar to the EP tube, add the above aqueous solution first, turn on the magnetic stirrer (speed about 1500-2000 rpm, so that the liquid surface is vortexed), and at room temperature, quickly inject the organic phase solution into the aqueous solution at an organic phase to aqueous phase volume ratio of 1:3, and continue stirring for 2 min to ensure that the miRNA and lipids are fully mixed and homogeneous. The LNP / miR-3065-5p solution is formed by self-assembly using the ethanol injection method.
[0083] ④ Dialysis purification: Add the obtained LNP / miR-3065-5p solution to a dialysis cup and dialyze with PBS for 4 hours (replace with fresh PBS every 2 hours) to remove ethanol and unencapsulated free substances, and finally obtain purified LNP / miR-3065-5p solution.
[0084] ⑤ Preparation of negative control: Following the same methods as ①~④ above, only the miR-3065-5p mimic was replaced with the negative control (NC mimic) sequence to prepare an LNP / NC solution, which was used as a negative control.
[0085] 2. Determination of particle size and zeta potential of LNP / miR-3065-5p sample
[0086] The particle size and zeta potential of LNP / miR-3065-5p and LNP / NC particles were determined using a nanoparticle size potential analyzer. Samples for particle size analysis were dialyzed with PBS before analysis, while samples for zeta potential analysis were dialyzed with DEPC water before analysis.
[0087] The results are as follows Figure 11 As shown, the particle sizes of LNP / NC and LNP / miR-3065-5p are 142.7±1.4933 nm and 142.1±3.1193 nm, respectively, both less than 200 nm. The PDI values of the two LNP samples are 0.0805±0.0333 and 0.0804±0.0135, respectively, indicating that the prepared LNP particles have good uniformity. The Zeta potentials of the samples were measured after dialysis with pure water. The results showed that LNP / NC and LNP / miR-3065-5p were 5.5873±2.5246 mV and 15.8667±0.6104 mV, respectively, indicating that the particle surface carries a weak positive charge in the pure water system. Transmission electron microscopy (TEM) observations showed that LNP / miR-3065-5p was nearly spherical in shape, with uniform particles and a particle size of less than 200 nm, consistent with the particle size measurement results. These characterization results indicate that LNP preparation was successful.
[0088] 3. Detection of miRNA-LNP loading rate and stability
[0089] (1) Serum stability of LNP / miR-3065-5p was tested by nucleic acid electrophoresis:
[0090] Prepare LNP / miR-3065-5p and naked-miR-3065-5p (i.e., pure miR-3065-5p, 0.02 μg / μL). Dilute the miR-3065-5p concentration in LNP / miR-3065-5p to the same concentration (0.02 μg / μL) as naked-miR-3065-5p.
[0091] Prepare 600 μL EP tubes and add diluted LNP / miR-3065-5p solution and 19.8 μL of naked-miR-3065-5p to each tube. Add 6.6 μL of fetal bovine serum (i.e., maintain 25% FBS in the system) to each EP tube, mix well, and incubate at 37℃ for 0 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h, then take samples. Add an appropriate volume of 4% Triton X-100 to each sample (prepared using 1×TAE, with a Triton X-100 concentration of 2% in the system, the purpose of which is to release undegraded miR-3065-5p). Calculate the volume required for loading the same mass of miRNA into each sample, add 5×RNA loading buffer, and perform agarose gel electrophoresis for separation and gel imaging observation.
[0092] (2) The stability of LNP / miR-3065-5p RNase A (RNase) was tested by nucleic acid electrophoresis:
[0093] Sample preparation follows the same method as described above for serum stability.
[0094] Prepare 600 μL EP tubes. Take equal volumes of LNP / miR-3065-5p solution and naked miR-3065-5p solution, respectively. Add RNase A to achieve a final concentration of 5 μg / mL for both solutions (this concentration was determined in a preliminary experiment). Mix thoroughly and incubate at 37 ℃. Take samples at 0, 2, 4, 6, and 8 h of incubation. Add an appropriate volume of 4% Triton X-100 (Triton X-100 concentration in the system is 2%) to each sample. Calculate the volume required for loading the same mass of miRNA onto each sample. Add 5×RNA loading buffer and perform agarose gel electrophoresis for separation and gel imaging observation.
[0095] The results are as follows Figure 12As shown in Figure A, almost no free miRNA was detected in the LNP / miR-3065-5p sample. However, after the structure was disrupted by 2% Triton X-100, the encapsulated miRNA was released, indicating that LNP / miR-3065-5p has a high encapsulation efficiency for miR-3065-5p.
[0096] To investigate the stability of LNP-loaded miRNAs in serum and against RNases, agarose gel electrophoresis was used to record changes in miRNA band signals over prolonged incubation time to reflect miRNA degradation and to evaluate the stability of LNP-loaded miRNAs. Figure 12 As shown in Figure B, naked miRNA (naked-miR-3065-5p) showed a weak band signal in serum after 6 hours, indicating that the miRNA had been largely degraded. After 12 hours, the band signal disappeared, indicating that the miRNA was almost completely degraded. In contrast, LNP-encapsulated miRNA showed almost no significant change in band signal in serum from 1 to 24 hours, indicating that the miRNA encapsulated by LNP can stably exist in serum. Similarly, LNP-encapsulated miRNA remained stable under the corresponding concentration of RNase. Figure 12 C). Therefore, LNP has a significant protective effect on miRNA, slowing its degradation in serum and under RNase conditions.
[0097] 4. LNP / miR-3065-5p increases the sensitivity of pancreatic cancer cells to GEM.
[0098] To evaluate the intracellular delivery efficiency of LNP / miR-3065-5p, pancreatic cancer cells AsPC-1 and BxPC-3R were administered LNP / miR-3065-5p for 48 h, and miR-3065-5p expression was detected by RT-qPCR. U6 was used as an internal control. U6 stem-loop RT primers (internal control reverse transcription): GTCGATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACAAAATA (SEQ ID NO:16). U6 upstream primer (for internal control qPCR forward amplification): AGAGAAGATTAGCATGGCCCCTG (SEQ ID NO:17). Universal downstream primer (for qPCR reverse amplification): ATCCAGTGCAGGGTCCGAGG (SEQ ID NO:3).
[0099] The results showed that, compared with the control, intracellular miR-3065-5p expression was significantly upregulated after administration of LNP / miR-3065-5p, suggesting that LNP / miR-3065-5p has a good intracellular delivery effect. Figure 13 A, 13B).
[0100] AsPC-1 and BxPC-3R cells were treated with a combination of LNP / miR-3065-5p and GEM, and their growth curves were measured using CCK-8 assays to verify changes in cell sensitivity to GEM. Control cells were treated with a combination of LNP / NC and GEM. The results showed that under the combined treatment of LNP / miR-3065-5p and GEM, the cell viability of both AsPC-1 and BxPC-3R cells was significantly decreased compared to the control group. Figure 13 C, 13D), consistent with the effect of transfecting miR-3065-5p mimic.
[0101] To verify the effect of LNP / miR-3065-5p on the sensitivity of pancreatic cancer cells to gemcitabine (GEM), the CCK-8 assay was used to determine the half-maximal inhibitory concentration (IC50) of LNP / miR-3065-5p-treated pancreatic cancer cells AsPC-1 and BxPC-3R against GEM. 50 AsPC-1 and BxPC-3R cells were treated with 20 nM LNP / NC and LNP / miR-3065-5p, respectively, followed by co-incubation with different concentration gradients of GEM: 0, 0.015, 0.061, 0.244, 0.977, 3.906, 15.625, 62.5, and 250 μM. After 96 h of treatment, CCK-8 reagent was added for an additional 2 h of incubation. The absorbance was measured at 450 nm, and cell viability was calculated. The IC50 was then fitted to the target cell line. 50 value.
[0102] The results are as follows: In AsPC-1 cells, the LNP / NC group and the LNP / miR-3065-5p group showed significantly higher IC50 values for GEM. 50 The values were 0.4069±0.0656 μM and 0.1852±0.1061 μM, respectively. Figure 14 A) In BxPC-3R cells, the LNP / NC group and the LNP / miR-3065-5p group showed an IC50 response to GEM. 50 The values were 0.8414 ± 0.0312 μM and 0.4576 ± 0.0424 μM, respectively. Figure 14 B). Compared with the LNP / NC control group, the IC50 of AsPC-1 and BxPC-3R cells to GEM was significantly increased after LNP / miR-3065-5p combined with GEM treatment. 50 All values decreased significantly. These results indicate that LNP / miR-3065-5p can significantly enhance the sensitivity of drug-resistant pancreatic cancer cells to GEM.
[0103] 5. Validation of the effect of LNP / miR-3065-5p on gemcitabine sensitivity in pancreatic cancer using a nude mouse xenograft tumor model.
[0104] 5.1 Effects of LNP / miR-3065-5p on subcutaneous xenografts in nude mice
[0105] (1) Modeling: BxPC-3R cells were subcutaneously inoculated into BALB / c-Nude nude mice (Beijing Huafukang Biotechnology Co., Ltd.) to construct a xenograft tumor model. Each nude mouse was subcutaneously inoculated with 1×10⁻⁶ cells. 7 One BxPC-3R cell.
[0106] (2) Grouping: When the tumor volume to be transplanted reaches 50-100 mm 3 Mice were randomly divided into four groups: PBS group (control group), LNP / miR-3065-5p group, GEM group, and LNP / miR-3065-5p + GEM group, with six mice in each group.
[0107] (3) Administration: The prepared LNP / miR-3065-5p was concentrated to about 1 / 5 of its volume using an ultrafiltration tube. The LNP / miR-3065-5p group and the LNP / miR-3065-5p + GEM group were injected intratumorally with LNP / miR-3065-5p. Each mouse was given 1 mg / kg of miR-3065-5p twice a week. The PBS group and the GEM group were given the same volume of PBS. The weight changes of the mice were recorded after each administration. Each mouse in the GEM group and the LNP / miR-3065-5p + GEM group was injected intraperitoneally with gemcitabine hydrochloride 150 mg / kg once a week.
[0108] (4) Sample collection: Mice were sacrificed on day 25 after administration, and mouse tumor tissue was collected, weighed, photographed, embedded in paraffin, sectioned, and the expression of Ki67 and HMOX-1 was observed and compared by immunohistochemical staining.
[0109] The mice were in good condition and their weight remained stable during the experiment. Figure 15 B).
[0110] Tumor volume growth curve ( Figure 15 A) showed that, compared with the GEM monotherapy group, the tumor volume growth in the LNP / miR-3065-5p combined with GEM group was significantly slowed (P < 0.05) and significantly smaller than that in the PBS control group (P < 0.01). The experimental endpoint was the weighing of the dissected tumor, and the results are as follows: Figure 15 C and Figure 15As shown in Figure D: there was no significant difference in tumor weight between the LNP / miR-3065-5p monotherapy group (approximately 0.50 g) and the PBS group (approximately 0.51 g); the tumor weight in the GEM monotherapy group (approximately 0.38 g) was lower than that in the PBS group, but the difference was not statistically significant (ns); while the tumor weight in the combination therapy group further decreased to approximately 0.22 g, significantly lower than that in the PBS control group (P < 0.05). These in vivo experimental data indicate that LNP / miR-3065-5p combined with GEM can significantly inhibit tumor volume growth and enhance the sensitivity of subcutaneous pancreatic cancer xenografts to gemcitabine.
[0111] Ki67 is an important indicator of cell proliferation activity. Immunohistochemical staining results ( Figure 16 The results showed that, compared with the PBS control group, the expression levels of Ki67 were decreased in the GEM monotherapy group and the LNP / miR-3065-5p combined with GEM group; the expression levels of HMOX-1 were also decreased in the LNP / miR-3065-5p monotherapy group and the LNP / miR-3065-5p combined with GEM group. Specifically, the expression levels of Ki67 and HMOX-1 in the LNP / miR-3065-5p combined with GEM group were lower than those in the GEM monotherapy group. These results indicate that the proliferation of tumor cells in this group was significantly inhibited, and the combined administration of LNP / miR-3065-5p and GEM has an excellent inhibitory effect on tumor proliferation. In summary, the above animal experiments demonstrate that LNP / miR-3065-5p has a good GEM drug sensitizing effect.
[0112] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. Application of human HMOX-1 gene inhibitors in the preparation of drugs that improve the sensitivity of pancreatic cancer to gemcitabine.
2. Use according to claim 1, characterized in that, The human HMOX-1 gene inhibitor is an HMOX-1 siRNA, hsa-miR-3065-5p, or an hsa-miR-3065-5p mimic.
3. The application according to claim 2, characterized in that, Human HMOX-1 siRNA sequences: Sense: CAACAAGGAGAGCCCAGUCUUTT; Antisense: AAGACUGGGCUCUCCUUGUUGTT; hsa-miR-3065-5p sequence: UCAACAAAAUCACUGAUGCUGGA; hsa-miR-3065-5p analog sequence: Sense: UCAACAAAAUCACUGAUGCUGGA; Antisense: CAGCAUCAGUGAUUUUGUUGAUU.
4. Application of human HMOX-1 gene inhibitors in combination with gemcitabine in the preparation of drugs for the treatment of pancreatic cancer.
5. The application according to claim 4, characterized in that, The human HMOX-1 gene inhibitor is an HMOX-1 siRNA, hsa-miR-3065-5p, or an hsa-miR-3065-5p mimic.
6. A drug for improving the sensitivity of pancreatic cancer to gemcitabine, characterized in that, The active ingredient in the drug includes a human HMOX-1 gene expression inhibitor.
7. The drug according to claim 6, characterized in that, The human HMOX-1 gene inhibitor is an HMOX-1 siRNA, hsa-miR-3065-5p, or an hsa-miR-3065-5p mimic.
8. The drug according to claim 6, characterized in that, The drug is a lipid nanoparticle encapsulating a human HMOX-1 gene inhibitor.
9. The medicament according to claim 8, characterized in that, The lipid nanoparticles are human HMOX-1 gene inhibitors encapsulated in liposomes. The human HMOX-1 gene inhibitor is a human HMOX-1 siRNA, hsa-miR-3065-5p, or hsa-miR-3065-5p mimic.
10. A drug for treating pancreatic cancer, characterized in that, The active ingredients in the drug include a human HMOX-1 gene expression inhibitor and gemcitabine.
